The Pim-1 Protein Kinase Is an Important Regulator of MET Receptor Tyrosine Kinase Levels and Signaling

REFERENCES

• Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. 2003. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4:915–925. http://dx.doi.org/10.1038/nrm1261.
   PubMed Web of Science ®Google Scholar
• Stoker M, Gherardi E, Perryman M, Gray J. 1987. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327:239–242. http://dx.doi.org/10.1038/327239a0.
   PubMed Web of Science ®Google Scholar
• Mazzone M, Comoglio PM. 2006. The Met pathway: master switch and drug target in cancer progression. FASEB J. 20:1611–1621. http://dx.doi.org/10.1096/fj.06-5947rev.
   PubMed Web of Science ®Google Scholar
• Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE. 2011. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin. Invest. Drugs 20:1677–1684. http://dx.doi.org/10.1517/13543784.2011.631523.
   PubMed Web of Science ®Google Scholar
• Benvenuti S, Comoglio PM. 2007. The MET receptor tyrosine kinase in invasion and metastasis. J. Cell. Physiol. 213:316–325. http://dx.doi.org/10.1002/jcp.21183.
   PubMed Web of Science ®Google Scholar
• Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B. 1997. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16:68–73. http://dx.doi.org/10.1038/ng0597-68.
   PubMed Web of Science ®Google Scholar
• Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, Seiwert T, Christensen JG, Jagadeeswaran R, Krausz T, Vokes EE, Husain AN, Salgia R. 2008. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 47:1025–1037. http://dx.doi.org/10.1002/gcc.20604.
   PubMed Web of Science ®Google Scholar
• Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, Christie A, Valk PJ, Delwel R, Ngo V, Kutok JL, Dahlberg SE, Moreau LA, Byers RJ, Christensen JG, Vande Woude G, Licht JD, Kung AL, Staudt LM, Look AT. 2012. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat. Med. 18:1118–1122. http://dx.doi.org/10.1038/nm.2819.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039–1043. http://dx.doi.org/10.1126/science.1141478.
   PubMed Web of Science ®Google Scholar
• Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, Gibbs JB, Pan BS. 2007. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 67:2081–2088. http://dx.doi.org/10.1158/0008-5472.CAN-06-3495.
   PubMed Web of Science ®Google Scholar
• Nawijn MC, Alendar A, Berns A. 2011. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat. Rev. Cancer 11:23–34. http://dx.doi.org/10.1038/nrc2986.
   PubMed Web of Science ®Google Scholar
• Beharry Z, Zemskova M, Mahajan S, Zhang F, Ma J, Xia Z, Lilly M, Smith CD, Kraft AS. 2009. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol. Cancer Ther. 8:1473–1483. http://dx.doi.org/10.1158/1535-7163.MCT-08-1037.
   PubMed Web of Science ®Google Scholar
• Cen B, Mahajan S, Wang W, Kraft AS. 2013. Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Res. 73:3402–3411. http://dx.doi.org/10.1158/0008-5472.CAN-12-4619.
   PubMedGoogle Scholar
• Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ. 1996. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin. Cancer Res. 2:1627–1636.
   PubMed Web of Science ®Google Scholar
• Beharry Z, Mahajan S, Zemskova M, Lin YW, Tholanikunnel BG, Xia Z, Smith CD, Kraft AS. 2011. The Pim protein kinases regulate energy metabolism and cell growth. Proc. Natl. Acad. Sci. U. S. A. 108:528–533. http://dx.doi.org/10.1073/pnas.1013214108.
   PubMed Web of Science ®Google Scholar
• Cen B, Mahajan S, Zemskova M, Beharry Z, Lin YW, Cramer SD, Lilly MB, Kraft AS. 2010. Regulation of Skp2 levels by the Pim-1 protein kinase. J. Biol. Chem. 285:29128–29137. http://dx.doi.org/10.1074/jbc.M110.137240.
   PubMed Web of Science ®Google Scholar
• van Gorp AG, van der Vos KE, Brenkman AB, Bremer A, van den Broek N, Zwartkruis F, Hershey JW, Burgering BM, Calkhoven CF, Coffer PJ. 2009. AGC kinases regulate phosphorylation and activation of eukaryotic translation initiation factor 4B. Oncogene 28:95–106. http://dx.doi.org/10.1038/onc.2008.367.
   PubMed Web of Science ®Google Scholar
• Merrick WC, Hensold JO. 2001. Analysis of eukaryotic translation in purified and semipurified systems. Curr. Protoc. Cell Biol. Chapter 11:Unit 11.9. http://dx.doi.org/10.1002/0471143030.cb1109s08.
   Google Scholar
• Fuss IJ, Kanof ME, Smith PD, Zola H. 2009. Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr. Protoc. Immunol. Chapter 7:Unit 7.1. http://dx.doi.org/10.1002/0471142735.im0701s85.
   PubMedGoogle Scholar
• Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. 2012. Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 12:89–103. http://dx.doi.org/10.1038/nrc3205.
   PubMed Web of Science ®Google Scholar
• Fram ST, Wells CM, Jones GE. 2011. HGF-induced DU145 cell scatter assay. Methods Mol. Biol. 769:31–40. http://dx.doi.org/10.1007/978-1-61779-207-6_3.
   PubMedGoogle Scholar
• Xia Z, Knaak C, Ma J, Beharry ZM, McInnes C, Wang W, Kraft AS, Smith CD. 2009. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J. Med. Chem. 52:74–86. http://dx.doi.org/10.1021/jm800937p.
   PubMed Web of Science ®Google Scholar
• Gambarotta G, Pistoi S, Giordano S, Comoglio PM, Santoro C. 1994. Structure and inducible regulation of the human MET promoter. J. Biol. Chem. 269:12852–12857.
   PubMedGoogle Scholar
• Zuker M. 2003. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31:3406–3415. http://dx.doi.org/10.1093/nar/gkg595.
   PubMed Web of Science ®Google Scholar
• Shahbazian D, Parsyan A, Petroulakis E, Topisirovic I, Martineau Y, Gibbs BF, Svitkin Y, Sonenberg N. 2010. Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B. Mol. Cell. Biol. 30:1478–1485. http://dx.doi.org/10.1128/MCB.01218-09.
   PubMed Web of Science ®Google Scholar
• Shahbazian D, Roux PP, Mieulet V, Cohen MS, Raught B, Taunton J, Hershey JW, Blenis J, Pende M, Sonenberg N. 2006. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J. 25:2781–2791. http://dx.doi.org/10.1038/sj.emboj.7601166.
   PubMed Web of Science ®Google Scholar
• Cen B, Mahajan S, Wang W, Kraft AS. 2013. Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Res. 73:3402–3411. http://dx.doi.org/10.1158/0008-5472.CAN-12-4619.
   PubMedGoogle Scholar
• Vornlocher HP, Hanachi P, Ribeiro S, Hershey JW. 1999. A 110-kilodalton subunit of translation initiation factor eIF3 and an associated 135-kilodalton protein are encoded by the Saccharomyces cerevisiae TIF32 and TIF31 genes. J. Biol. Chem. 274:16802–16812. http://dx.doi.org/10.1074/jbc.274.24.16802.
   PubMed Web of Science ®Google Scholar
• Methot N, Song MS, Sonenberg N. 1996. A region rich in aspartic acid, arginine, tyrosine, and glycine (DRYG) mediates eukaryotic initiation factor 4B (eIF4B) self-association and interaction with eIF3. Mol. Cell. Biol. 16:5328–5334.
   PubMed Web of Science ®Google Scholar
• Tamburini J, Green AS, Bardet V, Chapuis N, Park S, Willems L, Uzunov M, Ifrah N, Dreyfus F, Lacombe C, Mayeux P, Bouscary D. 2009. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 114:1618–1627. http://dx.doi.org/10.1182/blood-2008-10-184515.
   PubMed Web of Science ®Google Scholar